Oncology (all articles)
Towards precision pain medicine for pain after cancer: guidelines for pain phenotyping using nociplastic pain criteria
16 May, 2023 | 14:35h | UTC
Commentary on Twitter
Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria https://t.co/SLTPMzHZwE pic.twitter.com/RTpaARWuAa
— Physio Meets Science (@PhysioMeScience) January 27, 2023
Article under a Creative Commons (CC BY-NC-ND 4.0) license
RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases
16 May, 2023 | 14:30h | UTC
Commentary on Twitter
RCT: In patients with untreated EGFR-mutated non-small cell lung cancer with brain metastases, gefitinib + chemo improved survival and PFS vs gefitinib, with manageable adverse events, and may be a viable first-line treatment. #NSCLC https://t.co/Oe6zHYVsPV pic.twitter.com/oUvs12pYS7
— JAMA Network Open (@JAMANetworkOpen) February 9, 2023
Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer
16 May, 2023 | 14:25h | UTCCommentaries:
Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine
An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders
15 May, 2023 | 13:02h | UTC
2023 Rectal cancer lexicon update | Revised consensus on terminology and staging
15 May, 2023 | 12:50h | UTC
Cohort Study | Following lifestyle recommendations linked to lower recurrence in high-risk breast cancer
15 May, 2023 | 12:48h | UTCCommentary: Adherence to healthy lifestyle found to cut breast cancer recurrence, mortality – HealthDay
Commentary on Twitter
Adherence to the @AmericanCancer and the @aicrtweets lifestyle recommendations before and after high-risk breast cancer treatment was associated with a 37% reduced risk of disease recurrence and a 58% reduction in mortality. https://t.co/sy6b8CGgr1
— JAMA Network Open (@JAMANetworkOpen) May 4, 2023
Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options
15 May, 2023 | 12:45h | UTC
Clinical Trial Update | Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer
15 May, 2023 | 12:43h | UTCOriginal Article: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Endocrinopathies from checkpoint inhibitors: incidence, outcomes, and management
12 May, 2023 | 13:36h | UTCRelated:
Cohort Study | Outcomes of surgery in cardiac angiosarcoma
12 May, 2023 | 13:35h | UTC
Commentary on Twitter
A study in #JACCCardioOnc from US national cancer database identifies 239 patients w/ rare cardiac tumor angiosarcoma:
🔸 Surgery is underutilized
🔸 Higher income, recentness of Dx, early stage, use of surgery, & #chemotherapy had a better outcome— JACC Journals (@JACCJournals) May 6, 2023
M-A | First‐line therapy for adults with advanced renal cell carcinoma
12 May, 2023 | 13:33h | UTCSummary: Initial treatment for adults with advanced kidney cancer (renal cell carcinoma) – Cochrane Library
RCT | Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma
12 May, 2023 | 13:18h | UTCNews Release: ChemoID platform-predicted treatments lead to longer survival for glioblastoma patients – University of Cincinnati
Commentary on Twitter
Online now: Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial https://t.co/y5GYCCgg3b
— Cell Reports Medicine (@CellRepMed) May 3, 2023
Uncertainties and controversies in axillary management of patients with breast cancer
11 May, 2023 | 11:53h | UTC
Neurosurgical interventions for cerebral metastases of solid tumors
11 May, 2023 | 11:48h | UTC
Single-arm study | Halting endocrine therapy for pregnancy not linked to increased breast cancer events vs. a control cohort
10 May, 2023 | 16:01h | UTCInterrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In women with previous breast cancer who temporarily discontinued adjuvant endocrine therapy to attempt pregnancy, the frequency of breast cancer events was below the prespecified safety threshold and similar to that in controls (POSITIVE trial). https://t.co/zM3f4SbgjE
— NEJM (@NEJM) May 3, 2023
Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials
10 May, 2023 | 15:54h | UTCEditorials:
Atrial Fibrillation With Modern Cancer Treatment: More Common Than We Think – JACC: CardioOncology
Commentary on Twitter
Annual incidence rate of #AFib assoc w/ anticancer drugs were ⬆️ in pts w/ hematologic malig. It was found for #ibrutinib 4.92 (95% CI: 2.91-8.31), #clofarabine 2.38 (95% CI: 0.66-8.55), & #ponatinib 2.35 (95% CI: 1.78-3.12) per 100 person-yrs https://t.co/W2RGMrE37F… pic.twitter.com/NnbmUVcci5
— JACC Journals (@JACCJournals) April 27, 2023
New ACR breast cancer screening guidelines call for earlier and more-intensive screening for high-risk women
9 May, 2023 | 14:50h | UTCGuideline: Breast Cancer Screening for Women at Higher-than-Average Risk: Updated Recommendations from the ACR
Effects of intraoperative fluorescence guidance for breast cancer lumpectomy surgery
9 May, 2023 | 14:48h | UTCIntraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery – NEJM Evidence
News Release: Study finds fluorescent guide can help detect tumor left behind after breast cancer surgery – Mass General Brigham
EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma
9 May, 2023 | 14:47h | UTC
Commentary on Twitter
🆕#CPG in press❕
EASL-ILCA Clinical Practice Guidelines on the management of #IntrahepaticCholangiocarcinoma
🆓Find it here👉https://t.co/buM8rgBU1F@EASLedu@EASLnews#iCCA#LiverTwitter pic.twitter.com/raR983x0qk
— Journal of Hepatology (@JHepatology) April 20, 2023
A review of modern imaging landscape for prostate cancer: a comprehensive clinical guide
9 May, 2023 | 14:34h | UTC
RCT | Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor–positive breast cancer
9 May, 2023 | 14:32h | UTCPostoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A | Quality of life after risk-reducing surgery for breast and ovarian cancer prevention
9 May, 2023 | 14:21h | UTC
M-A | Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer
9 May, 2023 | 14:24h | UTC
RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma
8 May, 2023 | 13:04h | UTCTislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Interim analysis of the RATIONALE-306 trial of 1st-line tislelizumab + chemo vs placebo + chemo in adv or metastatic oesophageal squamous cell carcinoma—median OS 17·2 mo (95% CI 15·8–20·1) vs 10·6 mo (9·3–12·1; HR 0·66, 95% CI 0·54–0·80; p<0·0001)https://t.co/25lyg2Ef0o pic.twitter.com/vizCPVd8bj
— The Lancet Oncology (@TheLancetOncol) April 18, 2023
RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association
8 May, 2023 | 13:02h | UTC
Commentary on Twitter
NEW: Final results from two randomised ph 3 trials of the STAMPEDE platform protocol suggest that enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. #pcsmhttps://t.co/P1uqzE4Wsv pic.twitter.com/l8U7DQZIoe
— The Lancet Oncology (@TheLancetOncol) May 4, 2023